Poloxamer‐linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high‐risk neuroblastoma with primary and acquired chemoresistance

High‐risk solid tumors continue to pose a tremendous therapeutic challenge due to multidrug resistance. Biological mechanisms driving chemoresistance in high‐risk primary and recurrent disease are distinct: in newly diagnosed patients, non‐response to therapy is often associated with a higher level...

Descripción completa

Detalles Bibliográficos
Autores principales: Alferiev, Ivan S., Guerrero, David T., Guan, Peng, Nguyen, Ferro, Kolla, Venkatadri, Soberman, Danielle, Pressly, Benjamin B., Fishbein, Ilia, Brodeur, Garrett M., Chorny, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910785/
https://www.ncbi.nlm.nih.gov/pubmed/35192728
http://dx.doi.org/10.1096/fj.202101830RR

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910785/
https://www.ncbi.nlm.nih.gov/pubmed/35192728
http://dx.doi.org/10.1096/fj.202101830RR

Ejemplares similares